Maxim Group Has $70 on GILD. Says It's A BUY. link
Inside Wall Street: Gilead for value, growth One of world's largest and profitable biotechs gains on its HIV and hepatitis drugs. By Gene Marcial Jason Kolbert, biotech analyst at investment firm Maxim Group said with a detailed market and product forecasts through 2020, Kolbert says that while the market will continue to weigh the HIV and hepatitis issues, he figures Gilead will generate significant free cash flow through the end of the decade. And combined with his fully diluted 2020 earnings estimate of $8.38 a share and a sum-of-the-parts valuation, he reaches a target price of $70 a share for the stock.